FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
This article was originally published in The Gray Sheet
Clinical studies in support of pre-market approval applications should ideally be randomized and blinded, FDA maintains in recent guidance.
You may also be interested in...
The agency prefers device pivotal trials to be randomized, double-blinded and controlled, but understands that this is “neither feasible nor practical” for some devices, according to a Nov. 7 final guidance.
A rundown by “The Gray Sheet” of the most significant 510(k) reform actions taken in 2011, what’s on deck for 2012 and what reform will mean to device makers in the near term.
Regulatory news includes new bills in the Senate, CDRH pact with LifeScience Alley and more.